JP2022163013A5 - - Google Patents

Download PDF

Info

Publication number
JP2022163013A5
JP2022163013A5 JP2022110518A JP2022110518A JP2022163013A5 JP 2022163013 A5 JP2022163013 A5 JP 2022163013A5 JP 2022110518 A JP2022110518 A JP 2022110518A JP 2022110518 A JP2022110518 A JP 2022110518A JP 2022163013 A5 JP2022163013 A5 JP 2022163013A5
Authority
JP
Japan
Prior art keywords
icp
glycosylated
antibody
antigen
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022110518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022163013A (ja
Filing date
Publication date
Priority claimed from PCT/US2017/024024 external-priority patent/WO2017172517A1/en
Application filed filed Critical
Publication of JP2022163013A publication Critical patent/JP2022163013A/ja
Publication of JP2022163013A5 publication Critical patent/JP2022163013A5/ja
Pending legal-status Critical Current

Links

JP2022110518A 2016-03-29 2022-07-08 グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法 Pending JP2022163013A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662314940P 2016-03-29 2016-03-29
US62/314,940 2016-03-29
US201662361298P 2016-07-12 2016-07-12
US62/361,298 2016-07-12
PCT/US2017/024024 WO2017172517A1 (en) 2016-03-29 2017-03-24 Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
JP2019503385A JP7572146B2 (ja) 2016-03-29 2017-03-24 グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019503385A Division JP7572146B2 (ja) 2016-03-29 2017-03-24 グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法

Publications (2)

Publication Number Publication Date
JP2022163013A JP2022163013A (ja) 2022-10-25
JP2022163013A5 true JP2022163013A5 (cg-RX-API-DMAC7.html) 2022-11-14

Family

ID=58489431

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019503385A Active JP7572146B2 (ja) 2016-03-29 2017-03-24 グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法
JP2022110518A Pending JP2022163013A (ja) 2016-03-29 2022-07-08 グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019503385A Active JP7572146B2 (ja) 2016-03-29 2017-03-24 グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法

Country Status (6)

Country Link
US (1) US12059474B2 (cg-RX-API-DMAC7.html)
EP (1) EP3436475A1 (cg-RX-API-DMAC7.html)
JP (2) JP7572146B2 (cg-RX-API-DMAC7.html)
KR (2) KR102778941B1 (cg-RX-API-DMAC7.html)
CN (1) CN109071636A (cg-RX-API-DMAC7.html)
WO (1) WO2017172517A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11933786B2 (en) 2015-03-30 2024-03-19 Stcube, Inc. Antibodies specific to glycosylated PD-L1 and methods of use thereof
SI3356404T1 (sl) * 2015-10-02 2021-11-30 F. Hoffmann-La Roche Ag Protitelesa proti PD1 in postopki uporabe
MA43028B1 (fr) 2015-10-02 2021-09-30 Hoffmann La Roche Anticorps bispécifiques pour pd1 et tim3
KR101928488B1 (ko) * 2016-01-15 2018-12-12 가톨릭대학교 산학협력단 페록시다신을 포함하는 무혈청 배지 첨가제 조성물 및 이의 이용
CN109195991B (zh) * 2016-03-29 2023-10-31 斯特库比股份有限公司 对糖基化pd-l1特异的双重功能抗体及其使用方法
EP3568157A4 (en) * 2017-01-13 2021-01-06 National Research Council of Canada METHOD FOR OPTIMIZING THE PEPTIDE IMMUNO-EPITOP BY GLYCOSYLATION, OPTIMIZED PEPTIDE THEREOF AND ITS USE FOR CONJUGATE VACCINES
KR102461885B1 (ko) 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
CA3052532A1 (en) 2017-04-05 2018-10-11 F. Hoffmann-La Roche Ag Bispecific antibodies specifically binding to pd1 and lag3
JP2020522562A (ja) * 2017-06-06 2020-07-30 ストキューブ アンド シーオー., インコーポレイテッド Btn1a1又はbtn1a1リガンドに結合する抗体及び分子を用いて癌を治療する方法
EP3694545A4 (en) 2017-10-11 2021-12-01 Board Of Regents, The University Of Texas System HUMAN PD-L1 ANTIBODIES AND METHOD OF USING THEM
EP4501355A3 (en) 2018-03-23 2025-04-30 Board Of Regents, The University Of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
US11976128B2 (en) 2018-03-23 2024-05-07 Board Of Regents, The University Of Texas System Human PD-L2 antibodies and methods of use therefor
EP3768723A4 (en) 2018-03-23 2021-12-29 Board of Regents, The University of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
WO2019195621A1 (en) * 2018-04-04 2019-10-10 Immutics, Inc. Methods and compositions for blocking interaction between non-glycosylated pd-1 polypeptides
US20210156866A1 (en) * 2018-06-07 2021-05-27 Board Of Regents, The University Of Texas System Detection of immune checkpoint molecules by deglycosylation
BR112021013193A2 (pt) 2019-01-07 2021-09-28 Shattuck Labs, Inc. Proteínas heterodiméricas para modulação de células t gama delta
CN111751545A (zh) * 2019-03-28 2020-10-09 中国科学院上海药物研究所 一种筛选pd-l1/pd-1检测点抑制剂的方法
EP4007591A4 (en) * 2019-08-02 2023-11-29 Janssen Biotech, Inc. Materials and methods for multidirectional biotransportation
WO2021041704A1 (en) * 2019-08-29 2021-03-04 Truebinding, Inc. Antibodies and blocking the interaction of vista and its binding partner
CN114585644A (zh) * 2019-08-30 2022-06-03 艾吉纳斯公司 抗cd96抗体及其使用方法
CN110456079B (zh) * 2019-09-20 2020-06-02 四川大学华西医院 Tapbp自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
KR20220088428A (ko) * 2019-09-26 2022-06-27 주식회사 에스티큐브앤컴퍼니 글리코실화된 ctla-4에 대해 특이적인 항체 및 이의 사용 방법
KR20220088438A (ko) * 2019-10-09 2022-06-27 주식회사 에스티큐브앤컴퍼니 글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
CN111574627A (zh) * 2020-05-11 2020-08-25 潘宗富 抗vsig4单克隆抗体及其用途
CN111995683B (zh) * 2020-09-02 2022-03-11 福州迈新生物技术开发有限公司 抗pd-l1蛋白单克隆抗体、细胞株及其制备方法和应用
CN116139275B (zh) * 2021-11-19 2026-02-17 复旦大学 Cd300ld抑制剂在制备预防、诊断或治疗肿瘤产品中的用途
KR20240154675A (ko) * 2022-03-16 2024-10-25 주식회사 에스티큐브앤컴퍼니 Btn1a1 결합 단백질 및 이의 이용 방법
WO2023192976A1 (en) 2022-04-01 2023-10-05 Board Of Regents, The University Of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
AU2023375543A1 (en) * 2022-11-09 2025-06-12 Senti Biosciences, Inc. Antigen-binding domains and methods of use thereof
CN115807090B (zh) * 2022-11-17 2025-06-17 中国医学科学院肿瘤医院 Slamf9在肿瘤免疫治疗中的应用
CN115991780B (zh) * 2022-12-29 2025-06-10 盖普思药业(重庆)有限公司 一种抗人血小板胶原蛋白受体gp-vi抗体或其抗原结合片段及其应用
CN118878686A (zh) * 2024-08-13 2024-11-01 中山大学孙逸仙纪念医院 一种靶向糖基化pd-l1蛋白的单链抗体及其制备方法与应用
CN120078878A (zh) * 2025-03-20 2025-06-03 复旦大学附属中山医院 Tim-3蛋白在治疗肝损伤中的应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US20030148406A1 (en) 1992-03-17 2003-08-07 David John King Multivalent antigen-binding proteins
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US6982323B1 (en) 1997-12-23 2006-01-03 Alexion Pharmaceuticals, Inc. Chimeric proteins for diagnosis and treatment of diabetes
US20020064528A1 (en) 2000-01-28 2002-05-30 Zhenping Zhu Antibodies specific to KDR and uses thereof
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
WO2003049745A1 (en) 2001-12-12 2003-06-19 Pharmacia Corporation Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
DE10303664A1 (de) * 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
US20050281815A1 (en) 2004-02-26 2005-12-22 Dani Eshel CD40 splice variants and their uses
EP1725585A2 (en) 2004-03-10 2006-11-29 Lonza Ltd Method for producing antibodies
ES2427147T3 (es) 2004-06-30 2013-10-29 Mayo Foundation For Medical Education And Research Anticuerpo sHlgM12 útil para tratar esclerosis múltiple
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2007124361A2 (en) 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
US20080118978A1 (en) 2006-04-28 2008-05-22 Takashi Sato Anti-tumor agent
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
CA2706425A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
WO2009089149A1 (en) * 2008-01-03 2009-07-16 The Johns Hopkins University B7-h1 (cd274) antagonists induce apoptosis of tumor cells
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
EP2198884A1 (en) 2008-12-18 2010-06-23 Centre National de la Recherche Scientifique (CNRS) Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5
WO2010142534A1 (en) 2009-05-27 2010-12-16 Ablynx Nv Biparatopic protein constructs directed against il-23
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
CA2791648A1 (en) 2010-03-01 2011-09-09 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof
CN102321923B (zh) 2011-05-30 2014-04-16 江苏大学 肿瘤粘蛋白糖肽抗原决定部位的单克隆抗体库的制备方法
US9556281B2 (en) 2011-08-15 2017-01-31 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein A
EP2755688A4 (en) 2011-10-27 2014-08-06 Nkt Therapeutics Inc HUMANIZED ANTIBODIES AGAINST INKT
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
CA2874117C (en) 2012-07-02 2021-10-12 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical agent comprising anti-bmp9 antibody as active ingredient for treatment of anemia such as renal anemia and cancer anemia
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
US10202454B2 (en) 2013-10-25 2019-02-12 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
ES2763429T5 (es) 2013-12-17 2023-06-21 Hoffmann La Roche Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
US20170106065A1 (en) 2013-12-31 2017-04-20 Bavarian Nordic A/S Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
EP3277320A4 (en) 2015-03-30 2018-08-01 Stcube, Inc. Antibodies specific to glycosylated pd-l1 and methods of use thereof
SI3356404T1 (sl) 2015-10-02 2021-11-30 F. Hoffmann-La Roche Ag Protitelesa proti PD1 in postopki uporabe
CN109152798B (zh) 2015-12-02 2022-10-21 斯特库比股份有限公司 特异于糖基化的pd-1的抗体及其使用方法
KR102803158B1 (ko) 2015-12-02 2025-05-08 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도

Similar Documents

Publication Publication Date Title
KR102602417B1 (ko) G-단백질 커플화 수용체를 표적화하는 항체 및 이의 사용 방법
JP5457009B2 (ja) ヒトに適合したモノクローナル抗体における使用法
JP6055593B2 (ja) トロポニンiに対する抗体およびこれらの使用法
JP6391574B2 (ja) 種間標的内交差反応性を有する抗体分子を産生する方法
US6346249B1 (en) Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
US20080003617A1 (en) Methods for the identification and the isolation of epitope specific antibodies
JP2011526249A5 (cg-RX-API-DMAC7.html)
JP2009509538A5 (cg-RX-API-DMAC7.html)
JP2017524362A5 (cg-RX-API-DMAC7.html)
JP2021512604A5 (cg-RX-API-DMAC7.html)
TW202434888A (zh) 用於偵測及測定包括生物流體在內之流體中之蛋白質結構及穩定性的方法
WO2025077519A1 (zh) 抗人tigit抗体或其功能性片段及其应用
JP2016529213A5 (cg-RX-API-DMAC7.html)
WO2001030393A2 (en) Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products
JP7424718B2 (ja) 抗原の処理方法。
JP2019513004A5 (cg-RX-API-DMAC7.html)
JP6785372B2 (ja) 多重特異性分子の機能分析のためのsprに基づく二重結合アッセイ
WO2019077951A1 (ja) Muc1に対する抗体またはその抗原結合断片、それらのコード遺伝子、およびその用途
WO2025108395A1 (zh) 抗人pvrig抗体及其应用
US20240262929A1 (en) Anti-muc16 antibodies
WO2025213712A1 (zh) 基于ai从头设计筛选合成的her2蛋白特异性结合抗体及其应用
KR20250140106A (ko) 인간 항-pd-l2 항체 및 이의 용도
CN116162158B (zh) 结合bp特异性抗原肽的人源抗体、制备方法及用途
Ma et al. Generation and optimisation of antibodies for biosensor applications
CN117586397A (zh) 抗人cd147的单克隆抗体、表达载体、细胞株及其应用